+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 85 Pages
  • October 2023
  • GlobalData
  • Amgen Inc.
  • ID: 1322529
Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Amgen Inc (Amgen) is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc Key Recent Developments

  • Oct 09,2023: Amgen acquires Horizon Therapeutics for $27.8bn
  • Sep 20,2023: Amgen Launches Partners of Choice Network of Eight Leading Oncology Academic Centers
  • Aug 04,2023: Senderra Specialty Pharmacy announces that HUMIRA biosimilar products are now available to patients nationwide
  • Aug 03,2023: Amgen Reports Second Quarter Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Amgen Inc - Key Facts
  • Amgen Inc - Key Employees
  • Amgen Inc - Key Employee Biographies
  • Amgen Inc - Major Products and Services
  • Amgen Inc - History
  • Amgen Inc - Company Statement
  • Amgen Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Amgen Inc - Business Description
  • Business Segment: Human Therapeutics
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Other Revenue
  • Overview
  • Performance
  • Geographical Segment: Rest of the world (ROW)
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Amgen Inc - Corporate Strategy
  • Amgen Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Amgen Inc - Strengths
  • Amgen Inc - Weaknesses
  • Amgen Inc - Opportunities
  • Amgen Inc - Threats
  • Amgen Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Amgen Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Oct 09, 2023: Amgen acquires Horizon Therapeutics for $27.8bn
  • Sep 20, 2023: Amgen Launches Partners of Choice Network of Eight Leading Oncology Academic Centers
  • Aug 04, 2023: Senderra Specialty Pharmacy announces that HUMIRA biosimilar products are now available to patients nationwide
  • Aug 03, 2023: Amgen Reports Second Quarter Financial Results
  • Jul 18, 2023: The Alliance for Genomic Discovery Announces Founding Biopharma Members: Abbvie, Amgen, Astrazeneca, Bayer, and Merck
  • May 18, 2023: Sanofi applauds supreme court ruling supporting scientific innovation by striking down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
  • May 16, 2023: FTC sues to block biopharmaceutical giant Amgen from acquisition that would entrench monopoly drugs used to treat two serious illnesses
  • May 16, 2023: Amgen responds to FTC action re: proposed acquisition of Horizon Therapeutics
  • May 09, 2023: Amgen and TScan Therapeutics announce collaboration to identify novel targets in Crohn’s Disease
  • Apr 27, 2023: AMGEN reports first quarter financial results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • Contact Us
  • Disclaimer
List of Tables
  • Amgen Inc, Key Facts
  • Amgen Inc, Key Employees
  • Amgen Inc, Key Employee Biographies
  • Amgen Inc, Major Products and Services
  • Amgen Inc, History
  • Amgen Inc, Other Locations
  • Amgen Inc, Subsidiaries
  • Amgen Inc, Joint Venture
  • Amgen Inc, Key Competitors
  • Amgen Inc, Ratios based on current share price
  • Amgen Inc, Annual Ratios
  • Amgen Inc, Interim Ratios
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Amgen Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Amgen Inc, Performance Chart (2018 - 2022)
  • Amgen Inc, Ratio Charts
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Celgene Corp
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Clovis Oncology Inc
  • AbbVie Inc
  • Regeneron Pharmaceuticals Inc
  • Janssen Pharmaceuticals Inc
  • GSK plc
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Coherus BioSciences Inc
  • Millennium Pharmaceuticals Inc
  • Eli Lilly and Co
  • Repligen Corp
  • Momenta Pharmaceuticals Inc
  • Processa Pharmaceuticals Inc
  • Janssen Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • RenovoRx Inc
  • AbbVie Inc
  • Pfenex Inc
  • Eli Lilly and Co
  • Achillion Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Coherus BioSciences Inc
  • Millennium Pharmaceuticals Inc
  • Clovis Oncology Inc
  • Genentech USA Inc
  • Celgene Corp
  • Fresenius Medical Care AG & Co KGaA
  • Curis Inc
  • Takeda Pharmaceutical Co Ltd
  • Sanofi
  • Cassava Sciences Inc
  • Mylan Institutional Inc
  • Regeneron Pharmaceuticals Inc
  • Ra Pharmaceuticals Inc
  • GSK plc